

Last updated: Nov. 15, 2011

ONCOLOGY

TREATMENT TYPE	STUDY ID	STUDY NAME	PHASE	SPONSOR	PI	STUDY CONTACT NAME	STUDY CONTACT PHONE NUMBER
ALL ONCOLOGY DISEASE TYPES	ALTE03N1	Key Adverse Events after Childhood Cancer	N/A	COG	Kathy Meeske, Ph.D	Susan Caso	323-361-7685
ALL ONCOLOGY DISEASE TYPES	ACCRN07	Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research	N/A	COG	Leo Mascarenhas, MD	Susan Caso	323-361-7685
ALL ONCOLOGY DISEASE TYPES	ALTE07C1	Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer	N/A	COG	Sharon O'Neil, PhD	Susan Caso	323-361-7685
ADRENAL TUMOR	ARAR0332	Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy	3	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
ALL	AALL06N1	A Study of Neurocognitive Function in Children Treated for ALL	N/A	COG	David Freyer, DO, MS	Judith Andaya	323-361-8892

ALL	09-00180	Thromboelastography of patients with newly diagnosed ALL during induction	N/A	CHLA Investigator Initiated	Guy Young, MD	Christine Tam	323-361-5505
ALL	AALL0434	Intensified Methotrexate, Nelarabine (Compound 506U78; IND # 52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma	3	COG	John Quinn, MD	Judith Andaya	323-361-8892
ALL	AALL08B1	Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)	N/A	COG	Paul Gaynon, MD	Felicia Romagnoli	323-361-2121 x 24121
ALL	AALL0932	Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)	3	COG	Paul Gaynon, MD	Felicia Romagnoli	323-361-2121 x 24121
ALL	T2008-002	Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse	1	TACL	Paul Gaynon, MD	Judith Andaya	323-361-8892
ALL	AALL0433	Intensive Treatment For Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A randomized Trial of Vincristine Strategies	3	COG	Theresa Harned, MD	Felicia Romagnoli	323-361-2121 x 24121

ALL	AALL05B1	Protocol for Collecting and Banking Relapsed Acute Lymphoblastic	N/A	COG	Theresa Harned, MD	Judith Andaya	323-361-8892
ALL	T2009-007	A Phase I Study Testing the Safety of EZN-3042 When Given by Itself and with Chemotherapy for Children with Relapsed Acute Lymphoblastic Leukemia (ALL)	1	TACL	Theresa Harned, MD	Judith Andaya	323-361-8892
ALL AML	T2009-002	Clofarabine with Cytarabine for MRD Positive Leukemia	1	TACL	Paul Gaynon, MD	Judith Andaya	323-361-8892
ALL AML HODGKIN'S DISEASE	T2009-012	A Phase I Dose Finding Study Of Panobinostat In Children With Refractory Hematologic Malignancies	1	TACL	Paul Gaynon, MD	Judith Andaya	323-361-8892
AML	AAML1031	A Phase III Randomized Trial for Patients with de novo AML using Bortezomib (IND# 58443, NSC# 681239) and Sorafenib (BAY 43-9006, IND#69896, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD	2/3	COG	Cecilia Fu, MD	Felicia Romagnoli	323-361-2121 x 24121
AML	AAML0431	The Treatment of Down Syndrome Children with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) under the age of 4 years	3	COG	David Freyer, DO, MS	Felicia Romagnoli	323-361-2121 x 24121

AML	AAML0631	Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox® IND# 103, 331) during Consolidation	3	COG	Theresa Harned, MD	Judith Andaya	323-361-8892
BONE & SOFT TISSUE TUMORS	ABTR01B1	Protocol for Collecting and Banking Ped. Research Specimens	N/A	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
BRAIN - MEDULLOBLASTOMA	ACNS0332	Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patient	3	COG	Girish Dhall, MD	Kelley Haley	323-361-2480
BRAIN TUMOR	CCI-09-00335	Phase I Trial of Dasatinib, Lenalidomide, and Temozolomide in patients with Relapsed or Refractory Central Nervous System (CNS) Tumors	1	CHLA Investigator Initiated	Girish Dhall, MD	Kelley Haley	323-361-2480
BRAIN TUMOR	ACNS0333	Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation	3	COG	Jonathan Finlay, MD	Kelley Haley	323-361-2480

<p>BRAIN TUMOR (MEDULLOBLASTOMA)</p>	<p>ACNS0331</p>	<p>A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial</p>	<p>3</p>	<p>COG</p>	<p>Jonathan Finlay,MD</p>	<p>Kelley Haley</p>	<p>323-361-2480</p>
<p>BRAIN TUMOR(GERM CELL TUMOR)</p>	<p>CCI-09-00196</p>	<p>A Phase II Clinical Trial of Induction Chemotherapy Regimen Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single Cycle of High Dose Chemotherapy (HDC) And Autologous Hematopoietic STEM Cell Rescue (AuHSCR) for Patients with Recurrent or Progressive Intracranial Germ Cell Tumors</p>	<p>2</p>	<p>CHLA Investigator Initiated</p>	<p>Girish Dhall, MD</p>	<p>Kelley Haley</p>	<p>323-361-2480</p>
<p>BRAIN TUMORS</p>	<p>ACNS02B3</p>	<p>Protocol For Collecting and Banking Pediatric Brain Tumor Research Specimens</p>	<p>N/A</p>	<p>COG</p>	<p>Jonathan Finlay,MD</p>	<p>Kelley Haley</p>	<p>323-361-2480</p>
<p>BRAIN TUMORS (EPENDYMOMA)</p>	<p>ACNS0831</p>	<p>Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years</p>	<p>3</p>	<p>COG</p>	<p>Girish Dhall, MD</p>	<p>Kelley Haley</p>	<p>323-361-2480</p>

BRAIN TUMORS (GLIOMAS)	ACNS0822	A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High Grade Glioma	3	COG	Girish Dhall, MD	Kelley Haley	323-361-2480
BRAIN TUMORS (MEDULLOBLASTOMA)	ACNS0334	A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate	3	COG	Jonathan Finlay, MD	Kelley Haley	323-361-2480
EWING SARCOMA	AEWS07B1	A COG Study for Collecting and Banking Ewing Sarcoma Specimens	N/A	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
EWING SARCOMA	AEWS0331	European Ewing Tumor Working Initiative of National Groups Ewing Tumour Studies	3	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
EWING SARCOMA	AEWS1031	A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma	3	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319

HEPATOBLASTOMA	AHEP0731	Treatment of Children with All Stages of Hepatoblastoma	3	COG	Raj Venkatramani, MD	Jennifer Harrington	323-361-7319
HODGKIN'S DISEASE	AHOD04B1	Hodgkin Disease (HD) Banking Study	N/A	COG	Cecilia Fu, MD	Felicia Romagnoli	323-361-4121
HODGKIN'S DISEASE	AHOD0831	A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma	3	COG	John Quinn, MD	Felicia Romagnoli	323-361-4121
HOPE/LIFE	ACCL0431	A Randomized Phase III Study of Sodium Thiosulfate for the Prevention of Cisplatin Induced Otoxicity in Children	3	COG	David Freyer, DO, MS	Leah Reichman	323-361-5973
HOPE/LIFE	ACCL05C1	A Groupwide, Prospective Study of Otoxicity Assessment in Children Receiving Cisplatin Chemotherapy	N/A	COG	David Freyer, DO, MS	Leah Reichman	323-361-5973
HOPE/LIFE	CCI-07-00107	The Impact of Cancer for Older Adolescent and Young Adults Measuring Outcomes and Enhancing Care	N/A	CHLA Investigator Initiated	Kathy Meeske, PhD	Leah Reichman	323-361-5973
KIDNEY TUMOR	AREN03B2	Renal Tumors Classification, Biology and Banking	N/A	COG	David Tishler, MD	Jennifer Harrington	323-361-7319

LATE EFFECTS	ALTE05N1	Umbrella long term follow up		COGq	Kathy Meeske, Ph.D	Susan Caso	323-361-7685
NASOPHARYNGEAL TUMOR	ARAR0331	Treatment of Childhood Nasopharyngeal Carcinoma with Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy	3	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
NEURAL TUMOR REGISTRY	CCI-06-00198	Neural Tumors Registry	N/A	CHLA Investigator Initiated	Shahab Asgharzadeh,MD	Renee Almassizadeh	323-361-5642
NEUROBLASTOMA	ANBL0032	Randomized Study of Chimeric Antibody 14.18 (Ch 14.18) in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue	3	COG	Araz Marachelian, MD	Armi Bui	323-361-7203
NEUROBLASTOMA	ANBL00B1	Neuroblastoma Biology Study	N/A	COG	Araz Marachelian, MD	Armi Bui	323-361-7203
NEUROBLASTOMA	ANBL0532	Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma	3	COG	Araz Marachelian, MD	Armi Bui	323-361-7203
NEUROBLASTOMA	ANBL1021	Feasibility/Phase 2 study of hu14.18-IL2 + Isotretinoin in relapsed/refractory neuroblastoma		COG	Araz Marachelian, MD	Armi Bui	323-361-7203

NEUROBLASTOMA	N1999-02	Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulfoximine (BSO) (NSC-326321) with Autologous Stem Cell Support for Pediatric Extracranial Solid Tumors (NCI 68)	1	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695
NEUROBLASTOMA	N2004-03	A Phase I Study of Intravenous (Emulsion) Fenretinide (4-HPR, NSC 374551) in Children with Recurrent or Resistant Neuroblastoma (IND #70,058)	1	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695
NEUROBLASTOMA	N2004-04	Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-SorbTM(LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma.	1	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695
NEUROBLASTOMA	N2004-05	Neuroblastoma Biology Study	N/A	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695
NEUROBLASTOMA	N2007-02	A Phase I Study Of Bevacizumab With Bolus And Metronomic Cyclophosphamide And Zoledronic Acid In Children With Recurrent Or Refractory Neuroblastoma	1	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695
NEUROBLASTOMA	N2007-03	Vorinostat With 131I-MIBG Therapy For Resistant/Relapsed Neuroblastoma: A Phase I Study	1	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695

NEUROBLASTOMA	N2008-02	NANT 2008-02: Phase I Study of Vorinostat In Combination With 13-Cis-Retinoic Acid In Patients With Refractory/Recurrent Neuroblastoma	1	NANT	Araz Marachelian, MD	Scarlett Czarnecki	323-361-5695
OSTEOSARCOMA	AOST06B1	A Children's Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens	N/A	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
RECURRENT CANCER	ADVL0921	A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias	2	COG	Araz Marachelian, MD	Armi Bui	323-361-7203
RECURRENT CANCER	CCI- 09-00214	A Phase I study of Vincristine, Escalating Doses of Irinotecan, Temozolomide and Bevacizumab (VIT-B) in Pediatric and Adolescent Patients with Recurrent or Refractory Solid Tumors of Non-Hematopoietic Origin	1	CHLA Investigator Initiated	Rajkumar Venkatramani, MD	Jennifer Harrington	323-361-7319
RENAL TUMOR	AREN0321	Treatment of High Risk Renal Tumors	3	COG	David Tishler, MD	Jennifer Harrington	323-361-7319
RETINOBLASTOMA	AEPI05N1	Carcinogen Metabolism, DNA Repair, Parental Exposures, and Retinoblastoma	N/A	COG	Rima Jubran, MD	Armi Bui	323-361-7203

RETINOBLASTOMA	ARET0321	A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma	3	COG	Rima Jubran, MD	Armi Bui	323-361-7203
RHABDOMYOSARCOMA	D9902	A Group Wide Protocol for Collecting and Banking Pediatric Cancer Research Specimens, an Intergroup Rhabdomyosarcoma Study Group Protocol	N/A	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
RHABDOMYOSARCOMA	ARST0332	Risk-Based Treatment for Pediatric Non-Rhabdomyosarcoma Soft Tissue Sarcomas (NRSTS) in Patients Under 30 Years of Age	3	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
RHABDOMYOSARCOMA	ARST0531	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk Rhabdomyosarcoma (RMS)	3	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
RHABDOMYOSARCOMA	ARST08P1	A Groupwide Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND #100947, NSC # 742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk Rhabdomyosarcoma	Pilot Study	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319

RHABDOMYOSARCOMA	ARST0921	A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temozolomide (IND# 61010, Torisel) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma	2	COG	Leo Mascarenhas, MD	Jennifer Harrington	323-361-7319
WILMS TUMOR	AREN0532	Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor	3	COG	David Tishler, MD	Jennifer Harrington	323-361-7319
WILMS TUMOR	AREN0533	Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors	3	COG	David Tishler, MD	Jennifer Harrington	323-361-7319
WILMS TUMOR	AREN0534	Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor	3	COG	David Tishler, MD	Jennifer Harrington	323-361-7319

HEMATOLOGY

TREATMENT TYPE	STUDY ID	STUDY NAME	PHASE	SPONSOR	PI	STUDY CONTACT NAME	STUDY CONTACT PHONE NUMBER
BLEEDING DISORDER	09-00289	Inhibitor Development in Previously Untreated Patients (PUPs) or Minimally Blood Component-Treated Patients (MBCTPs) when Exposed to plasma-derived von Willebrand Factor-Containing Factor VIII (VWF/FVIII) Concentrates and to Recombinant Factor VIII (rFVIII) Concentrates: An Independent, International, Multicentre, Prospective, Controlled, Randomised, Open Label, Clinical Trial	4	CHLA Investigator Initiated	Guy Young, MD	Christine Tam	323-361-5505
BLOOD CLOTS	10-00106	Single Dose Pilot Study of oral rivarobaxin in pediatric subjects with venous thromboembolism	1	Bayer	Guy Young, MD	Christine Tam	323-361-5505
BLOOD CLOTS	11-00054	Longterm Follow Up data of Children Receiving Fondaparinux for treatment of deep vein thrombosis	N/A		Guy Young, MD	Christine Tam	323-361-5505
HEMOPHILIA	11-00098	Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients with Congenital Haemophilia and Inhibitors	3	Novo Nordisk	Guy Young, MD	Christine Tam	323-361-5505

HEMOPHILIA	11-00139	A Phase III, Multi-center, single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics of N9-GP when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Hemophilia B (Paradigm 2)	3	Novo Nordisk	Guy Young, MD	Christine Tam	323-361-5505
SICKLE CELL DISEASE	CCI-07-01448	Pulmonary Hypertension and Chronic Transfusion Therapy in Patients With Sickle Cell Anemia	N/A	CHLA - CTSI	John Wood, MD	Anne Nord	323-361-8507
SICKLE CELL DISEASE	CCI-11-00067	The Role of Glutamine in Red Cell Oxidative Stress and Viscosity in Subjects with Sickle Cell Trait.	Pilot Study	Foundation	John Wood, MD	Ani Dongelyan	323-361-2597
SICKLE CELL DISEASE	CCI-11-00083	Cerebral blood flow response to perturbations of oxygen tension in subjects with and without sickle cell disease.	N/A	NERI	John Wood, MD	Anne Nord	323-361-8507
SICKLE CELL DISEASE	CCI 09-00054	A Safety, and Efficacy Evaluation of Sodium Nitrite Injection for the Treatment of Vaso-Occlusive Crisis Associated with Sickle Cell Disease	2	Hope Pharmaceuticals	Thomas Coates, MD	Anne Nord	323-361-8507
SICKLE CELL DISEASE	CCI-09-00244	Iron Mediated Vascular Disease in Sickle Cell Anemia Patients	N/A	NIH	John Wood, MD	Anne Nord	323-361-8507
THALASSEMIA	CCI-03-240	Thalassemia Data and Blood Specimen Collection System	N/A	CDC	Thomas Coates, MD	Tatiana Hernandez	323-361-8827